Synthetic Biologics Stock Price

0.0501 (6.11%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthetic Biologics Inc SYN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0501 6.11% 0.87 19:59:59
Open Price Low Price High Price Close Price Prev Close
0.9247 0.841 0.93 0.851 0.8199
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
34,167 26,344,240 $ 0.8682004 $ 22,872,080 20,784,423 0.25 - 1.70
Last Trade Time Type Quantity Stock Price Currency
20:00:00 7,270 $ 0.851 USD

Synthetic Biologics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 32.15M 36.95M 36.89M $ - $ - -0.98 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Synthetic Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SYN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.720.970.680.832915825,228,6370.1520.83%
1 Month0.3511.700.34030.887685133,177,4300.519147.86%
3 Months0.33221.700.28330.872296210,983,5220.5378161.89%
6 Months0.521.700.2610.8451285,255,2650.3567.31%
1 Year0.541.700.250.81837412,787,4410.3361.11%
3 Years17.32520.2930.252.001,248,229-16.46-94.98%
5 Years58.4595.7250.2513.631,134,779-57.58-98.51%

Synthetic Biologics Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Your Recent History
Synthetic ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.